News - Aricept


Current filters:


Popular Filters

Eisai seeks expanded Japanese indication for Aricept

Eisai seeks expanded Japanese indication for Aricept


Japanese drug major Eisai says it has filed an application for its already marketed anti-Alzheimer's…


Pfizer revenues down as patent losses hit sales

Pfizer revenues down as patent losses hit sales


Global pharma giant Pfizer has said worldwide sales fell 2% to $12.6 billion, hurt by generic competition,…

AriceptEliquisEnbrelFinancialLipitorNorth AmericaPfizerPharmaceuticalRebifSpiriva

Insights on the US Alzheimer's disease market


The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

European Alzheimer's drug market to grow to $4.78 billion by 2019, says F&S


The patent expiry of all four existing European Medicines Agency-approved drugs for Alzheimer's disease…

AriceptEbixaEisaiEuropeExelon PatchLundbeckMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalResearch

Public Citizen sues FDA for failing to ban dangerous dose of Aricept


The Food and Drug Administration has dragged its feet for too long on a petition calling on the agency…

AriceptEisaiLegalNeurologicalNorth AmericaPfizerPharmaceuticalRegulation

Actavis to debut generic Aricept in EU markets as patents expire


Icelandic generics firm Actavis yesterday announced the launch of donepezil, a generic copy of Eisai…

ActavisAriceptdonepezilEisaiEuropeGenericsMarkets & MarketingNeurologicalPfizer

Eisai wins patent extension in Japan for blockbuster Alzheimer’s drug Aricept


Japanese drug major Eisai (TYO: 4523) says that the Supreme Court of Japan has turned down a petition…


Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top